-
Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ? (belinostat)
prnasia
January 24, 2022
IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ? (belinostat) in Europe, Middle East, North Africa, Russia, and CIS.
-
Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
FirstWordPharma
December 14, 2021
Newswise — The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being..
-
BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma
pharmatimes
August 06, 2021
Celgene (now a subsidiary of Bristol Myers Squibb) received accelerated FDA approval in 2011 for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who ...
-
Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
pharmafocusasia
December 03, 2018
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer......
-
FDA approves treatment for peripheral T-cell lymphoma
europeanpharmaceuticalreview
November 20, 2018
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program…
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
